Craniopharyngioma Clinical Trial
Official title:
Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma
Subjects with papillary craniopharyngioma harboring a BRAF mutation will be treated with a BRAF + MEK inhibitor (dabrafenib + trametinib) after informed consent. Study participants will be administered oral dabrafenib and trametinib until maximal tumor volume reduction assessed by MRI. Progression free survival, cognition, ophthalmologic status, hypothalamic status and quality of life will be assessed 1 year after initiation of study treatment
Background. Papillary craniopharyngioma harbours a BRAF mutation in 90% of cases. Treatment with BRAF + MEK (mitogen activated protein kinase ) inhibitors (dabrafenib + trametinib) may prevent patients from undergoing surgery with a high risk of serious side effects, or provide an additional treatment option when further surgery is not advised. Study intervention Subjects with newly diagnosed craniopharyngioma where radical surgery is not considered adequate or patients with recurrence of craniopharyngioma where further surgery is not considered possible without serious sequelae will be asked for informed consent Study participants are treated continuously with dabrafenib and trametinib orally, until maximal tumor shrinkage. Evaluation is done by MRI to measure tumor volume, as well as assessment of performance status, quality of life, cognition, ophthalmologic status, performance status and hypothalamic status. Study type The study is a Phase II, single armed, open label and multicenter study Study drugs are Dabrafenib (Tafinlar) and trametinib (Mekinist) Primary outcome To evaluate tumor response in the form of reduced tumor volume on MRI in patients with papillary craniopharyngioma during treatment with dabrafenib and trametinib. Secondary outcomes To evaluate dabrafenib and trametinib treatment for the following aspects: - response according to RECIST Duration of response for patients treated without subsequent surgery - how many patients become operable after neoadjuvant treatment - progression-free survival after 1 and 2 years - quality of life during and after treatment The effect of treatment on vision, cognition and hypothalamic effects Exploratory outcomes Levels of circulating BRAF Trial population 25 patients Trial duration Participants are treated with the study treatment for at least one year if the treatment is well tolerated, to maximum tumor reduction, or longer according to the investigators´s assessment. Treatment is discontinued in case of progression, unacceptable toxicity or at the request of the patient. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00949156 -
Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma
|
Phase 1 | |
Recruiting |
NCT05465174 -
Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
|
Phase 2 | |
Completed |
NCT02849743 -
Intranasal Oxytocin in Hypothalamic Obesity
|
Phase 2 | |
Completed |
NCT01272622 -
Prospective Study of Children and Adolescents With Craniopharyngioma
|
N/A | |
Recruiting |
NCT04158284 -
Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts
|
||
Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
Recruiting |
NCT06217848 -
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
|
Early Phase 1 | |
Completed |
NCT01881854 -
Sleep Wake and Melatonin Pattern in Craniopharyngioma
|
N/A | |
Active, not recruiting |
NCT00517959 -
SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
|
Phase 3 | |
Not yet recruiting |
NCT06299891 -
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
|
Phase 2 | |
Completed |
NCT02842723 -
Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)
|
Phase 2 | |
Recruiting |
NCT02792582 -
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
|
Phase 2 | |
Completed |
NCT01484873 -
Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
|
Phase 2 | |
Withdrawn |
NCT03708913 -
Neuromodulation for Hypothalamic Obesity
|
N/A | |
Completed |
NCT02162732 -
Molecular-Guided Therapy for Childhood Cancer
|
N/A | |
Recruiting |
NCT00840047 -
Methionine PET/CT Studies In Patients With Cancer
|
Phase 2 | |
Recruiting |
NCT04087902 -
Long-Term Longitudinal QoL in Patients Undergoing EEA
|
||
Recruiting |
NCT04648462 -
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
|
||
Completed |
NCT04937335 -
Craniopharyngioma With Tumoral Hemorrhage
|
||
Completed |
NCT03330080 -
Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients
|